InnovivavsMerck & Company

INVA and MRK stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$132.59

Value $328B

-3.77%
MRK's page

Innoviva (INVA) has a market value of $1.4B and Merck & Company (MRK) $328B. Over the last year, with dividends, INVA moved -15.7% and MRK +41.6%. The P/E is 7.1 for INVA and 133.6 for MRK. Dividend yield: INVA none, MRK 2.56%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    INVA$1.4B

    MRK$328B

    MRK is 240 times INVA

  • Revenue, 12 months

    INVA$438M

    MRK$67.4B

    MRK is 154 times INVA

  • Net income, 12 months

    INVA$193M

    MRK$2.5B

    MRK is 13 times INVA

  • Operating margin

    INVA38.8%

    MRK–

  • ROIC

    INVA9.5%

    MRK3.9%

    5.6 points apart

  • P/E

    INVA7.1

    MRK133.6

    MRK is 19 times INVA

  • Dividend yield

    INVA0.0%

    MRK2.6%

    2.6 points apart

  • 5-year return

    INVA+7.6%

    MRK+86.0%

    78.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

INVA+7.6%

MRK+86.0%

10015020020222023202420252026
Returns by period
PeriodINVAWith dividendsMRKWith dividends
1 year since November 18, 2025-15.7%Price -15.7%+41.6%Price +37.5%
3 years since November 17, 2023+34.4%+10.4% a yearPrice +34.4%+42.8%+12.6% a yearPrice +30.3%
5 years since November 18, 2021+7.6%+1.5% a yearPrice +7.6%+86.0%+13.2% a yearPrice +59.7%
10 years since November 21, 2016+68.9%+5.4% a yearPrice +68.9%+202.6%+11.7% a yearPrice +123.0%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

INVAInnovivaMRKMerck & Company

Valuation

INVAMRK
Valuation
Price$18.45$132.59
Market value$1.4B$328B
Enterprise value (EV)$1.0B$372B
P/E7.1133.6
P/E, 5-year median6.114.8
P/B1.27.3
EV/EBIT6.178.1
Free cash flow yield13.4%4.5%

Results and growth

INVAMRK
Results and growth
Revenue, 12 months$438M$67.4B
Net income, 12 months$193M$2.5B
Free cash flow, 12 months$183M$14.7B
Earnings per share, 12 months$2.61$0.98
Revenue growth, year on year14.7%1.3%
Revenue growth a year, past+4.1%over 5 years+9.4%over 5 years
EPS growth a year, past+10.3%over 5 years+21.2%over 5 years

Margins and returns on capital

INVAMRK
Margins and returns on capital
Gross margin74.5%71.8%
Operating margin38.8%–
Net margin44.1%3.6%
ROIC9.5%3.9%
ROE16.4%5.2%

Balance sheet

INVAMRK
Balance sheet
Cash$581M$9.7B
Total debt$270M$53.8B
Net debt / EBITDA–5.7
Interest cover8.6×2.4×

Dividends and buybacks

INVAMRK
Dividends and buybacks
Dividend yield–2.6%
Dividend per share, 12 months–$3.40
Dividend growth a year, past–+5.8%over 5 years
Buyback yield0.3%1.6%
Shareholder yield0.3%4.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: INVA or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, Innoviva or Merck & Company?

By market value, Merck & Company ($328B) is about 239.9 times Innoviva ($1.4B), at today's prices.

How did INVA and MRK stock do over the last 10 years?

Since November 21, 2016, INVA's price moved +68.9% and MRK's +123.0%. With dividends: INVA +68.9% (+5.4% a year), MRK +202.6% (+11.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, INVA or MRK?

The dividend yield at today's price is none for Innoviva and 2.56% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.

What is the P/E of INVA and MRK?

At today's price, the P/E is 7.1 for INVA and 133.6 for MRK. The median of the last five years was 6.1 and 14.8, which shows where each stands against its own past.

Which has the higher profit margins, Innoviva or Merck & Company?

Over the last twelve months, the net margin was 44.1% for Innoviva and 3.6% for Merck & Company, and the operating margin 38.8% and –. Revenue was $438M and $67.4B.

Which is the better investment, Innoviva or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.